FIREBRICK PHARMA LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.069 AUD | +16.95% |
|
+23.21% | +38.00% |
| 01:10am | Firebrick Pharma Launches Nasodine Nasal Spray in Singapore | MT |
| 23/05 | Firebrick Pharma Obtains Nasodine Composition Patent in South Africa | MT |
Valuation
| Fiscal Period: June | 2022 | 2023 |
|---|---|---|
| Capitalization 1 | 44.74 | 27.32 |
| Enterprise Value (EV) 1 | 37.6 | 24.96 |
| P/E ratio | -8.13 x | -3.88 x |
| Yield | - | - |
| Capitalization / Revenue | 41.3 x | 1,211 x |
| EV / Revenue | 34.7 x | 1,107 x |
| EV / EBITDA | -10.7 x | -3.7 x |
| EV / FCF | -1,59,54,123 x | -77,94,279 x |
| FCF Yield | -0% | -0% |
| Price to Book | 5.4 x | 11 x |
| Nbr of stocks (in thousands) | 1,68,844 | 1,76,247 |
| Reference price 2 | 0.2650 | 0.1550 |
| Announcement Date | 23/08/22 | 29/08/23 |
1AUD in Million2AUD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: June | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| Net sales 1 | 0.509 | 0.422 | 1.083 | 0.0226 |
| EBITDA 1 | -1.499 | -2.439 | -3.502 | -6.742 |
| EBIT 1 | -1.499 | -2.44 | -3.509 | -6.752 |
| Operating Margin | -294.51% | -578.15% | -323.93% | -29,941.76% |
| Earnings before Tax (EBT) 1 | -1.498 | -2.439 | -3.796 | -6.802 |
| Net income 1 | -1.498 | -2.439 | -3.796 | -6.802 |
| Net margin | -294.41% | -577.97% | -350.42% | -30,164.4% |
| EPS 2 | -0.0495 | -0.0662 | -0.0326 | -0.0400 |
| Free Cash Flow | - | -0.9452 | -2.356 | -3.203 |
| FCF margin | - | -223.98% | -217.52% | -14,203.19% |
| FCF Conversion (EBITDA) | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - |
| Dividend per Share | - | - | - | - |
| Announcement Date | 25/01/22 | 25/01/22 | 23/08/22 | 29/08/23 |
1AUD in Million2AUD
Estimates
Balance Sheet Analysis
| Fiscal Period: June | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| Net Debt 1 | - | - | - | - |
| Net Cash position 1 | 0.04 | 1.16 | 7.15 | 2.35 |
| Leverage (Debt/EBITDA) | - | - | - | - |
| Free Cash Flow | - | -0.95 | -2.36 | -3.2 |
| ROE (net income / shareholders' equity) | - | -252% | -77.3% | -126% |
| ROA (Net income/ Total Assets) | - | -126% | -41.8% | -72.1% |
| Assets 1 | - | 1.932 | 9.079 | 9.439 |
| Book Value Per Share 2 | 0.0100 | 0.0400 | 0.0500 | 0.0100 |
| Cash Flow per Share 2 | 0 | 0.0300 | 0.0400 | 0.0100 |
| Capex | - | 0.02 | 0.03 | 0 |
| Capex / Sales | - | 3.81% | 3% | 7.17% |
| Announcement Date | 25/01/22 | 25/01/22 | 23/08/22 | 29/08/23 |
1AUD in Million2AUD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| +38.00% | 77.21L | |
| +48.79% | 78TCr | |
| +41.51% | 64TCr | |
| +19.43% | 33TCr | |
| +7.18% | 29TCr | |
| +17.42% | 25TCr | |
| 0.00% | 22TCr | |
| +11.28% | 22TCr | |
| +4.53% | 16TCr | |
| -3.92% | 16TCr |
- Stock Market
- Equities
- FRE Stock
- Financials Firebrick Pharma Limited
